Diseases, Conditions, Syndromes

Empagliflozin—kidney protection regardless of an initial 'eGFR dip'

Empagliflozin (EMPA), a selective inhibitor of sodium/glucose cotransporter 2 (SGLT2 inhibitors, "gliflozines"), reduces CKD progression in type 2 diabetics (T2D) with cardiovascular disease, presumably by lowering intraglomerular ...

Cardiology

Nonglycemic factors up risk for peripheral neuropathy in T1DM

(HealthDay)—Several nonglycemic factors may increase the risk for the development of diabetic peripheral neuropathy (DPN) among people with type 1 diabetes (T1D), according to a study recently published in Diabetes Care.

Diseases, Conditions, Syndromes

New tool predicts five-year risk of chronic kidney disease

A new risk calculator tool that uses a mix of variables including age, hypertension, and diabetes status can be used to predict accurately whether someone is likely to develop chronic kidney disease within five years. The ...

Diseases, Conditions, Syndromes

SGLT2 inhibitors protect against kidney disease in T2DM

(HealthDay)—A class of diabetes drugs, called sodium-glucose co-transporter-2 (SGLT2) inhibitors, protect against kidney disease in patients with type 2 diabetes, according to a review published online Sept. 5 in The Lancet ...

page 1 from 13